Beleave Inc. operates as a medical cannabis company in Canada. More Details
+ 2 more risks
Overvalued with worrying balance sheet.
Share Price & News
How has Beleave's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: Insufficient data to determine BE's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine BE's volatility change over the past year.
7 Day Return
1 Year Return
Return vs Industry: BE underperformed the Canadian Pharmaceuticals industry which returned -9.6% over the past year.
Return vs Market: BE underperformed the Canadian Market which returned -8.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Beleave's share price compared to the market and industry in the last 5 years?
Simply Wall St News
7 months ago | Simply Wall StWhat Kind Of Investor Owns Most Of Beleave Inc. (CSE:BE)?
9 months ago | Simply Wall StDoes Beleave (CSE:BE) Have A Healthy Balance Sheet?
11 months ago | Simply Wall StThe Beleave (CSE:BE) Share Price Is Down 91% So Some Shareholders Are Rather Upset
Is Beleave undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BE is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: BE is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BE is good value based on its PB Ratio (0.5x) compared to the CA Pharmaceuticals industry average (1.4x).
How is Beleave forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Beleave has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of BE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Beleave competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Beleave performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BE is currently unprofitable.
Growing Profit Margin: BE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BE is unprofitable, and losses have increased over the past 5 years at a rate of 50.9% per year.
Accelerating Growth: Unable to compare BE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (35.9%).
Return on Equity
High ROE: BE has a negative Return on Equity (-312.52%), as it is currently unprofitable.
How is Beleave's financial position?
Financial Position Analysis
Short Term Liabilities: BE's short term assets (CA$2.7M) do not cover its short term liabilities (CA$16.9M).
Long Term Liabilities: BE's short term assets (CA$2.7M) exceed its long term liabilities (CA$1.2M).
Debt to Equity History and Analysis
Debt Level: BE's debt to equity ratio (213.7%) is considered high.
Reducing Debt: Insufficient data to determine if BE's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if BE has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Beleave current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BE's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bill Panagiotakopoulos (44 yo)
Mr. Vasilios Panagiotakopoulos, also known as Bill, has been Chief Restructuring Officer at Beleave Inc. since June 2020. Mr. Panagiotakopoulos serves as Chief Executive officer at Beleave Inc. since April...
CEO Compensation Analysis
Compensation vs Market: Bill's total compensation ($USD0.00) is below average for companies of similar size in the Canadian market ($USD177.48K).
Compensation vs Earnings: Bill's compensation has increased whilst the company is unprofitable.
|CEO, COO||0.58yr||CA$2.23m||1.16% |
|Co-Founder & Chief Science Officer||no data||CA$466.00k||no data|
|Interim Chief Financial Officer||0.58yr||no data||no data|
|Director of Operations||no data||no data||no data|
|VP of Sales||2.33yrs||no data||no data|
|Head of Veteran Affairs & Community Outreach||4.42yrs||no data||no data|
Experienced Management: BE's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
|CEO, COO||0.58yr||CA$2.23m||1.16% |
|Independent Chairman of the Board & Member of Advisory Board||no data||no data||1.33% |
|Director||1.08yrs||no data||4.22% |
Experienced Board: BE's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.6%.
Beleave Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Beleave Inc.
- Ticker: BE
- Exchange: CNSX
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$2.769m
- Shares outstanding: 553.87m
- Website: https://beleave.com
- Beleave Inc.
- 2030 Bristol Circle
- Suite 115
- L6H 0H2
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BE||CNSX (Canadian National Stock Exchange)||Yes||New Common Shares||CA||CAD||Dec 2015|
|4B9||DB (Deutsche Boerse AG)||Yes||New Common Shares||DE||EUR||Dec 2015|
|BLEV.F||OTCPK (Pink Sheets LLC)||Yes||New Common Shares||US||USD||Dec 2015|
Beleave Inc. operates as a medical cannabis company in Canada. The company cultivates and sells medical and recreational cannabis products. It also operates a network of medical cannabis clinics in Ontario...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/03 01:09|
|End of Day Share Price||2020/08/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.